PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Administration, Intranasal”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources

Reproductive endocrine effects of intranasal administration of progesterone to adult female rhesus monkeys.

Adult female rhesus monkeys exhibiting normal ovulatory menstrual cycles were treated with progesterone nasal sprays. Animals in group A (n = 9) were treated with the solvent only (controls). Animals in groups B (n = 6), C (n = 17) and D (n = 7), respectively, were treated with a daily dose of 0.4, 2 and 10 micrograms of progesterone and the spraying was done between days 5-14 of the cycle. Ovulation was monitored by laparoscopy on day 20. The serum endocrine profile throughout the treated menstrual cycle was studied with respect to oestradiol and progesterone. Bioactive luteinizing hormone (bLH) was studied in blood samples taken on the day of the mid-cycle oestradiol peak, 2 days before, and 2 days after. The menstrual cycle was divided into two phases with respect to the mid-cycle oestradiol peak: phase I was taken to include day 1 of the cycle to the day of the oestradiol peak, and the remaining part of the menstrual cycle was considered to be phase II. The serum-endocrine profile in the controls was similar to that observed in normal ovulatory menstrual cycles. However, in the progesterone-treated groups three types of menstrual cycles were discernable on the basis of the serum endocrine profile. In the type I menstrual cycle, observed only in group C (n = 10), the mid-cycle bLH peak was abolished and the progesterone levels remained low throughout the cycle. Laparoscopy revealed these to be anovulatory cycles.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Intranasal↗

Nasal lesions induced by intranasal administration of benzaikonium chloride in rats.

We investigated the lesions of nasal cavity mucous membrane caused by administration of 0.01, 0.05 and 0.10 w/v% Benzalkonium chloride (BZC) solutions in the nasal cavity of rats. No BZC-induced symptoms or nasal lesions were seen in the 0.01 w/v% BZC-treated group. On the other hand, BZC-induced symptoms such as nasal sound and rubbing the nose with forelegs were observed in the 0.05 and 0.10 w/v% BZC-treated groups. Additionally, BZC-induced lesions, including epithelial desquamation, inflammation and edema, occurred in the anterior nasal cavity in the 0.05 and 0.10 w/v% BZC-treated groups, but these lesions were confined to the dorsal meatus and the adjacent nasal septum. These results indicate that 0.01 w/v% BZC solution has no effect on the nasal cavity mucous membrane. However, 0.05 and 0.10 w/v% BZC solutions induce lesions in the nasal cavity mucous membrane due to their irritating effect.

Administration, Intranasal↗

Intranasal administration of fusidic acid cream in leprosy.

The effect of local treatment of nostrils with fusidic acid cream was investigated in 30 previously untreated lepromatous leprosy patients. The cream was applied in the nostrils after flushing the nostrils with normal saline, twice a day for a period of four weeks. It was found that 20 mg/gm of sodium fusidate was effective in reducing the morphological index of the nose-blow smear to zero in two weeks in majority of the patients. No untoward side effect was seen in any of the patients. Such nasal treatment along with multidrug therapy may help in reducing the patient's level of infectiousness to their contacts, since the nose is recognized to be an important portal of exit of M. leprae.

Administration, Intranasal↗

[An intensification of antiviral and interferon effects of ridostin (an interferon inducer) by cationic liposomes in vitro and in intranasal administration].

Combined application of ridostine with catonic liposomes was shown to essentially enhance the interferon-inducing and antiviral activity of the former in experiments with cell cultures L-929, which is apparently related with an improved efficiency of intracellular delivery of dsRNA. A comparative study demonstrated that ridostine, when combined with liposomes, is needed by 10(3)-10(4) times less as when it is used alone. A pretreatment of the cellular monolayer by cationic liposomes contributes also to enhancing the activity of ridostine, which can be explained by an enhanced permeability of cells for dsRNA holding on-for as long as 30 minutes after the removal of liposomes from the liquid culture. A separate successive administration of, first, liposomes and, then, of ridostine in BALB/c mice (20 mg/kg) leads to a more intensified induction of interferon in the upper respiratory tract tissues as compared with the administration of ridostine alone.

Administration, Intranasal↗